Concepts in the use of TRAIL/Apo2L: An emerging biotherapy for myeloma and other neoplasias

Expert Opinion on Investigational Drugs

Volumn 10, Issue 8, 2001, Pages 1521-1530

  Mitsiades, N ^a   Mitsiades, C S ^a   Poulaki, V ^a   Anderson, K C ^a   Treon, S P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apo2 ligand; B cells; Caspase; FLIP; Multiple myeloma; NF B; Plasma cells; TNF related apoptosis inducing ligand; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 8; CELL RECEPTOR; CIAP 2 PROTEIN; CYTOTOXIC AGENT; DOXORUBICIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; GROWTH FACTOR; HLA DR5 ANTIGEN; I KAPPA B; INTERLEUKIN 6; LIGAND; PROTEIN INHIBITOR; PROTEOSOME INHIBITOR; REGULATOR PROTEIN; SN 50; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; B LYMPHOCYTE; BONE MARROW; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER TRANSPLANTATION; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; DRUG TOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MONONUCLEAR CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL; PLASMACYTOMA; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; DOXORUBICIN; ENZYME INHIBITORS; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; NEOPLASMS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034895563     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.8.1521     Document Type: Review

References (93)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
3. Apoptosis signaling by death receptors
4. The receptor for the cytotoxic ligand TRAIL
5. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
6. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
7. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
8. Characterization of two receptors for TRAIL
9. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
10. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
11. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
12. A novel receptor for Apo2L/TRAIL contains a truncated death domain
13. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
14. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
15. Inhibition of death receptor signals by cellular FLIP
16. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
17. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells
18. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
19. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand
20. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
21. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
22. Lethal effect of the anti-Fas antibody in mice
23. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
24. TNF-related apoptosis-inducing ligand/Apo2L selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications
25. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and express DR4 and DR5 receptors
26. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
27. TRAIL induces differentiation-stage specific apoptosis in B-cell malignancies, overcomes drug resistance in multiple myeloma and its anti-myeloma effect is enhanced by doxorubicin NF-κB inhibition
28. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
29. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
30. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
31. Apoptosis and Fas expression in human fetal membranes
32. Fas ligand-induced apoptosis as a mechanism of immune privilege
33. A role for CD95 ligand in preventing graft rejection
34. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
35. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege
36. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
37. APO2 ligand: A novel lethal weapon against malignant glioma?
38. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells
39. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line
40. Fas-mediated apoptosis in peripheral primitive neuroectodermal tumor (PNET) /Ewing's sarcoma (ES)
41. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
42. Safety and antitumor activity of recombinant soluble Apo2 ligand
43. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
44. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
45. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
46. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
47. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome Type II
48. CD95/Fas/Apo-1 mediated signal transduction
49. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
50. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
51. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
52. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance
53. Rare loss-of-function mutation of a death receptor gene in head and neck cancer
54. Molecular determinants of response to TRAIL in killing of normal and cancer cells
55. Expression of TRAIL and its receptors in human brain tumors
56. Functional analysis of TRAIL receptors using monoclonal antibodies
57. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
58. Differential modulation of apoptosis sensitivity in CD95 Type I and Type II cells
59. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD- 95-induced apoptosis
60. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase
61. Multiple myeloma: Increasing evidence for a multistep transformation process
62. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
63. Advances in the biology of multiple myeloma: Therapeutic applications
64. Multiple myeloma
65. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
66. Bone marrow transplantation in multiple myeloma
67. Interleukin-6 prevents dexamethasone-induced myeloma cell death
68. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
69. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma
70. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma
71. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma
72. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
73. KILLER/DR5 is a DNA damage-inducible p53-regulated receptor gene
74. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
75. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
76. Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2
77. TRAIL-induced apoptosis of thyroid cancer cells: Potential for therapeutic intervention
78. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation
79. Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells
80. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: Inhibition by bisindolylmaleimide
81. Multiple signals converging on NF-kappaB
82. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
83. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways
84. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
85. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2
86. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells
87. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
88. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
89. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control
90. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
91. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines
92. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
93. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL